Enhancing Participation in Clinical Trials
An in-depth thought leadership whitepaper explaining how sponsors can operationalize the FDA’s 2025 guidance on inclusive and representative clinical trial design. It outlines current industry challenges (e.g., restrictive eligibility criteria, participant burden, placement uncertainty), summarizes the FDA’s updated expectations, and demonstrates how ClinSphere® Trial IntelX™ enables data-driven protocol design, burden reduction, optimized site selection, and realistic subgroup planning to align with regulatory requirements from the start.
Download White Paper
